Cargando…

Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses

Although antibodies that effectively neutralize a broad set of influenza viruses exist in the human antibody repertoire, they are rare. We used a single-cell screening technology to identify rare monoclonal antibodies (MAbs) that recognized a broad set of influenza B viruses (IBV). The screen yielde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vigil, Adam, Estélles, Angeles, Kauvar, Lawrence M., Johnson, Scott K., Tripp, Ralph A., Wittekind, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923107/ https://www.ncbi.nlm.nih.gov/pubmed/29507069 http://dx.doi.org/10.1128/AAC.02269-17

Ejemplares similares

Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies
por: Vigil, Adam, et al.
Publicado: (2020)

Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus
por: Su, Hang, et al.
Publicado: (2021)

Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins
por: Marjuki, Henju, et al.
Publicado: (2016)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection
por: Lim, Jeremy J., et al.
Publicado: (2020)

Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation
por: Maertens, Johan, et al.
Publicado: (2020)

Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants
por: Ishimaru, Hanako, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
por: Griffin, M. Pamela, et al.
Publicado: (2017)

Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
por: Zumbrun, Elizabeth E., et al.
Publicado: (2022)

Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies
por: Kirkpatrick Roubidoux, Ericka, et al.
Publicado: (2022)

A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance
por: Urbanowicz, Richard A., et al.
Publicado: (2016)

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study
por: Li, Yinjuan, et al.
Publicado: (2021)

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
por: Yuan, Mengqi, et al.
Publicado: (2022)

Protamine Sulfate Is a Potent Inhibitor of Human Papillomavirus Infection In Vitro and In Vivo
por: Young, Jesse M., et al.
Publicado: (2022)

A truncated HIV Tat demonstrates potent and specific latency reversal activity
por: Van Gulck, Ellen, et al.
Publicado: (2023)

Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase
por: Bonnard, Damien, et al.
Publicado: (2023)

Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial
por: Dong, Run, et al.
Publicado: (2022)

Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans
por: Rijal, Pramila, et al.
Publicado: (2020)

Antigenic Characterization of Human Monoclonal Antibodies for Therapeutic Use against H7N9 Avian Influenza Virus
por: Chang, Pengxiang, et al.
Publicado: (2022)

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
por: Detalle, Laurent, et al.
Publicado: (2015)

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity
por: Rubio, Adonis A., et al.
Publicado: (2021)

Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies
por: Kamal, Ram P., et al.
Publicado: (2017)

TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
por: Bam, Rujuta A., et al.
Publicado: (2016)

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
por: Tsiang, Manuel, et al.
Publicado: (2016)

Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses
por: Beltran-Pavez, Carolina, et al.
Publicado: (2022)

Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies
por: Wang, Wei, et al.
Publicado: (2018)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
por: Lawitz, Eric J., et al.
Publicado: (2016)

Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility
por: Farrukee, R., et al.
Publicado: (2018)

6′-β-Fluoro-Homoaristeromycin and 6′-Fluoro-Homoneplanocin A Are Potent Inhibitors of Chikungunya Virus Replication through Their Direct Effect on Viral Nonstructural Protein 1
por: Kovacikova, Kristina, et al.
Publicado: (2020)

SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses
por: Carnell, George W., et al.
Publicado: (2021)

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19
por: Good, Steven S., et al.
Publicado: (2021)

Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens
por: Nuñez Castrejon, Ana M., et al.
Publicado: (2022)

Enisamium Reduces Influenza Virus Shedding and Improves Patient Recovery by Inhibiting Viral RNA Polymerase Activity
por: te Velthuis, Aartjan J. W., et al.
Publicado: (2021)

Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers
por: Schorcht, Anna, et al.
Publicado: (2020)

Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model
por: Farooqui, Amber, et al.
Publicado: (2015)

Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
por: Ma, Huan, et al.
Publicado: (2021)

Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies
por: Kim, Soohyun, et al.
Publicado: (2022)

Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters
por: Takamatsu, Yuki, et al.
Publicado: (2022)

Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies
por: Cheeseman, Hannah M., et al.
Publicado: (2016)

Influenza A(H7N9) Virus Acquires Resistance-Related Neuraminidase I222T Substitution When Infected Mallards Are Exposed to Low Levels of Oseltamivir in Water
por: Gillman, Anna, et al.
Publicado: (2015)

Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection
por: Takemori, Toshitada, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i39m9q6hrhu81ss38anq2jrl90